Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program

Table 1 Univariate association (HR [95% CI]) of individual baseline liver markers with CV and renal outcomes

	HF (n = 243)	CV death (n = 453)	HF or CV death (n = 652)	All deaths (n = 681)	MACE (n = 1011)	Renal endp.^a (n = 847)
Top quartile
ALT	0.73 [0.52–0.99]	0.59 [0.45–0.75]	0.63 [0.51–0.77]	0.64 [0.52–0.78]	0.84 [0.72–0.98]	0.75 [0.64–0.89]
AST	1.04 [0.76–1.39]	0.80 [0.63–1.01]	0.89 [0.73–1.07]	0.89 [0.74–1.07]	0.99 [0.85–1.14]	0.94 [0.80–1.10]
ALP	1.51 [1.15–1.98]	1.48 [1.20–1.81]	1.46 [1.23–1.72]	1.44 [1.21–1.69]	1.28 [1.11–1.47]	1.28 [1.10–1.48]
γGT	1.85 [1.42–2.40]	1.03 [0.83–1.28]	1.29 [1.09–1.53]	1.18 [0.94–1.33]	1.10 [0.95–1.26]	1.06 [0.90–1.23]
Bilirubin	1.23 [0.93–1.63]	0.82 [0.64–1.02]	0.95 [0.78–1.13]	0.85 [0.70–1.02]	1.00 [0.86–1.15]	0.94 [0.80–1.10]
Log [baseline]
ALT [U/L]	0.62 [0.46–0.82]	0.52 [0.42–0.64]	0.55 [0.46–0.66]	0.55 [0.46–0.65]	0.84 [0.73–0.96]	0.72 [0.62–0.84]
AST [U/L]	1.03 [0.71–1.47]	0.64 [0.48–0.85]	0.75 [0.59–0.94]	0.74 [0.59–0.93]	0.91 [0.76–1.09]	0.80 [0.66–0.98]
ALP [U/L]	1.88 [1.24–2.83]	1.75 [1.29–2.38]	1.68 [1.30–2.17]	1.54 [1.20–1.98]	1.43 [1.16–1.75]	1.51 [1.21–1.89]
γGT [U/L]	1.65 [1.39–1.95]	1.14 [0.99–1.31]	1.30 [1.17–1.46]	1.13 [1.09–1.27]	1.17 [1.06–1.28]	1.08 [0.98–1.20]
Bilirubin [µM]	1.07 [0.81–1.41]	0.87 [0.71–1.08]	0.94 [0.79–1.12]	0.85 [0.72–1.01]	1.02 [0.88–1.17]	0.85 [0.73–0.98]

Table entries are hazard ratio (HR) and 95% confidence interval. Statistically significant estimates are in bold
ALT alanine aminotransferase; AST aspartic aminotransferase; γGT gamma-glutamyl transferase; ALP alkaline phosphatase; CV cardiovascular; HF hospitalized heart failure; MACE major adverse cardiovascular events
^aRenal endp. = composite of a > 40% decline in estimated glomerular filtration rate, renal replacement, renal death, and progression to macroalbuminuria

ISSN: 1475-2840